VEGFA and hydrops fetalis: These inhibitors have been associated with better outcomes in metastatic renal cell carcinoma patients on anti-VEGF therapies,29,30 potentially reducing HF incidence and underscoring the value of preventing and managing cardiovascular risks induced by these anticancer drugs.